Menu
Peptide Database
Results
No peptides found
Featured

Use search to browse all 100+ peptides

LL-37

Cathelicidin, hCAP-18, FALL-39, CAP-18

Quick Stats
Studies 2230
Trials 95
Score 2
2003 pubmed

Expression of LL-37 by human gastric epithelial cells as a potential host defense mechanism against Helicobacter pylori.

Hase. Koji K; Murakami. Masamoto M; Iimura. Mitsutoshi M; Cole. Sheri P SP; Horibe. Yoshimune Y; Ohtake. Takaaki T; Obonyo. Marygorret M; Gallo. Richard L RL; Eckmann. Lars L; Kagnoff. Martin F MF

Key Findings

  • LL-37 is normally expressed in surface, chief, and parietal cells of the stomach lining.
  • H. pylori infection markedly raises LL-37 levels in gastric epithelium and secretions, requiring the bacterium’s type IV secretion system.
  • The LL-37 peptide alone, and more so with human beta-defensin 1, kills several H. pylori strains in lab tests.

Practical Outcomes

  • While there’s no ready‑to‑use supplement or protocol yet, the study suggests that strategies to boost LL-37 (e.g., vitamin D optimization or other immune‑supportive approaches) might help protect the stomach against H. pylori. Keep an eye on future research for practical ways to enhance this natural peptide.

Summary

Your stomach lining makes a natural antimicrobial peptide called LL-37. When you have a Helicobacter pylori infection, the stomach cells crank up LL-37 production, and the peptide can directly kill the bacteria, especially when teamed up with another defense peptide. This shows LL-37 is part of the gut’s innate defense system.

Abstract

LL-37/human cationic antimicrobial peptide 18 (hCAP18) is a human cathelicidin with broad-spectrum antimicrobial, lipopolysaccharide binding, and chemotactic activities. This study examined the role of LL-37/hCAP18 in gastric innate immune defense by characterizing its constitutive and regulated expression by human gastric mucosa and its bactericidal activity against the gastric pathogen Helicobacter pylori. LL-37/hCAP18 messenger RNA expression in normal and H. pylori -infected gastric mucosa and gastric epithelial cells was determined by in situ hybridization, real-time polymerase chain reaction, immunostaining, and immunoblot analysis. Bactericidal activity was measured by using a colony-forming unit assay. LL-37/hCAP18 messenger RNA and protein were expressed in a distinct distribution by surface epithelial cells as well as chief and parietal cells in the fundic glands of normal gastric mucosa. LL-37/hCAP18 was significantly increased in the epithelium and gastric secretions of H. pylori -infected patients, but not in individuals with non-H. pylori -induced gastric inflammation. Infection of cultured gastric epithelial cells with a wild-type but not an isogenic Delta cagE mutant strain of H. pylori increased LL-37/hCAP18 expression, indicating that H. pylori -induced regulation of LL-37/hCAP18 production required an intact type IV secretion system. LL-37, the C-terminal peptide of LL-37/hCAP18, alone or in synergy with human beta-defensin 1, was bactericidal for several H. pylori strains. These data indicate that H. pylori up-regulates production of LL-37/hCAP18 by gastric epithelium and suggest this cathelicidin contributes to determining the balance between host mucosal defense and H. pylori survival mechanisms that govern chronic infection with this gastric pathogen.

Study Information

Provider

pubmed

Year

2003

DOI

10.1053/j.gastro.2003.08.028